Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/13/2026

1. CSCO
2. CBRS
3. COHR
4. SPY
5. STUB
6. EAT
7. BTGO
8. NVDA
9. WYFI
10. ARX

Go back to Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study
(NASDAQ: CNTB) Delayed: 2.54 +0.21 (9.01%)
Previous Close $2.33    52 Week High $ 
Open $2.33    52 Week Low $ 
Day High $2.64    P/E N/A 
Day Low $2.33    EPS $ 
Volume 805,556